These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 23532738

  • 1. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B, Tajeddine N, Vandersmissen P, Zanou N, Van Schoor M, Mondin L, Courtoy PJ, Tombal B, Gailly P.
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [Abstract] [Full Text] [Related]

  • 2. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.
    Prostate; 2012 Jun 01; 72(8):875-85. PubMed ID: 22072572
    [Abstract] [Full Text] [Related]

  • 3. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 4. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 5. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M, Neuwirt H, Cavarretta IT, Hobisch A, Culig Z.
    Prostate; 2007 Aug 01; 67(11):1194-201. PubMed ID: 17520660
    [Abstract] [Full Text] [Related]

  • 6. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 7. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 8. Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.
    Kaini RR, Sillerud LO, Zhaorigetu S, Hu CA.
    Prostate; 2012 Sep 15; 72(13):1412-22. PubMed ID: 22294520
    [Abstract] [Full Text] [Related]

  • 9. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ.
    J Cell Biochem; 2010 Aug 01; 110(5):1187-94. PubMed ID: 20589722
    [Abstract] [Full Text] [Related]

  • 10. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.
    Floyd MS, Teahan SJ, Fitzpatrick JM, Watson RW.
    Prostate Cancer Prostatic Dis; 2009 Aug 01; 12(1):25-33. PubMed ID: 18475288
    [Abstract] [Full Text] [Related]

  • 11. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.
    Prostate; 2009 May 15; 69(7):744-54. PubMed ID: 19152342
    [Abstract] [Full Text] [Related]

  • 12. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC.
    Prostate; 2010 Feb 01; 70(2):179-89. PubMed ID: 19790234
    [Abstract] [Full Text] [Related]

  • 13. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.
    Prostate; 2010 Aug 01; 70(11):1166-78. PubMed ID: 20333699
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Ricevuto E, Vicentini C, Bologna M.
    Prostate; 2007 Sep 01; 67(12):1255-64. PubMed ID: 17596848
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI, Kakouratos C, Kalamida D, Mitrakas A, Pouliliou S, Xanthopoulou E, Papadopoulou E, Fasoulaki V, Giatromanolaki A.
    Anticancer Drugs; 2018 Apr 01; 29(4):323-333. PubMed ID: 29381490
    [Abstract] [Full Text] [Related]

  • 16. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.
    Prostate; 2010 Apr 01; 70(5):457-66. PubMed ID: 19902465
    [Abstract] [Full Text] [Related]

  • 17. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J.
    Prostate; 2015 Aug 01; 75(11):1187-96. PubMed ID: 25894097
    [Abstract] [Full Text] [Related]

  • 18. Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells.
    Morrissey C, Brown M, O'Sullivan J, Weathered N, Watson RW, Tenniswood M.
    Int J Urol; 2007 Jun 01; 14(6):545-51. PubMed ID: 17593102
    [Abstract] [Full Text] [Related]

  • 19. Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
    Salman H, Bergman M, Blumberger N, Djaldetti M, Bessler H.
    Biomed Pharmacother; 2014 Feb 01; 68(1):21-4. PubMed ID: 24406295
    [Abstract] [Full Text] [Related]

  • 20. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z.
    Prostate; 2006 Mar 01; 66(4):413-20. PubMed ID: 16302272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.